Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $120.91 USD
Change Today -0.74 / -0.61%
Volume 1.6M
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BMRN) Key Developments

Biomarin Pharmaceutical Inc. Announces the Results of a Post-Hoc Sub-Analysis of the PKU-016 or ASCEND Study

BioMarin Pharmaceutical Inc. announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the large randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria (PKU) treated with the approved therapy Kuvan® (sapropterin dihydrochloride) at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting. The sub-analysis included 86 subjects 8 to 17 years of age with PKU who were randomized to blinded treatment with Kuvan (N = 43) or placebo (N = 43) for 13 weeks, after which all individuals received open label Kuvan for an additional 13 weeks. This analysis evaluated the effects of Kuvan treatment on blood phenylalanine (Phe) concentration, attention deficit hyperactivity disorder like symptoms, and executive function defects in children and adolescents with PKU. Symptoms of ADHD were evaluated by using the attention deficit hyperactivity rating scale (ADHD-RS) commonly used to evaluate symptoms of inattentiveness and hyperactivity. There was a statistically significant difference between the baseline and week 13 ADHD-RS total score with Kuvan compared with placebo (p = 0.01). In addition to the total ADHD-RS score, the sub-analysis showed a statistically significant (p= 0.04) improvement in the inattention subscale score and statistically significance (p= 0.016) improvement in the hyperactivity subscale score for the Kuvan group compared with placebo from baseline to week 13.

Shire, AstraZeneca And Roche Show Interest In BioMarin

After several media outlets reported that Shire plc (LSE:SHP), AstraZeneca PLC (LSE:AZN) and Roche Holding AG (SWX:ROG) are considering buying BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), SunTrust says that it would be logical for several drug companies looking to build or expand their orphan disease franchises to buy BioMarin.

Shire Reportedly Looking To Buy BioMarin Pharma

There are market speculations that Shire plc (LSE:SHP) is considering acquiring BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) in a $65 billion deal. The shares of Shire rose today because of the merger speculations and UBS AG's confidence in Shire.

Myriad Genetics, Inc. Announces Expansion of Collaboration with BioMarin Pharmaceutical Inc

Myriad Genetics Inc. announced an expansion of the company's collaboration with BioMarin Pharmaceutical Inc. Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed. Talazoparib is an investigational poly-ADP ribose polymerase (PARP) inhibitor being developed by BioMarin. In the expanded relationship, the companies also will collaborate under FDA regulations and guidelines for the development and potential regulatory approval requirements for both talazoparib and myChoice HRD. The expansion adds to an ongoing collaboration that began in September 2013, when BioMarin began using Myriad's BRACAnalysis CDx companion diagnostic test in its pivotal Phase 3 EMBRACA and Phase 2 ABRAZO clinical studies of talazoparib for advanced or metastatic breast cancer patients carrying BRCA mutations.

AstraZeneca Reportedly Mulls Acquisition Of Biomarin Pharmaceuticals

AstraZeneca PLC (LSE:AZN) is reportedly seeking acquisition of BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN). “Pharmaceutical giant AstraZeneca (AZN) has been rumored to be interested in buying BioMarin for $175 per share in cash,” British newspaper Daily Mail reported


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $120.91 USD -0.74

BMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $62.79 USD -0.89
Incyte Corp $101.66 USD -1.10
Jazz Pharmaceuticals PLC $187.18 USD -2.74
Pharmacyclics Inc $257.45 USD -0.57
Vertex Pharmaceuticals Inc $125.07 USD -3.87
View Industry Companies

Industry Analysis


Industry Average

Valuation BMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.0x
Price/Book 11.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at